Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084279 · ClinicalTrials.gov registry record · Phase 2
CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)
A Phase 2 study, sponsored by InterMune.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT00084279 is a Phase 2 study that has completed, run by InterMune. The registered enrollment target is 81 participants.
The verdict
NCT00084279, a Phase 2 study, has completed, sponsored by InterMune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin.
Interventions
- DRUG Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2004-04 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084279
The ClinicalTrials.gov registry entry for NCT00084279 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin is the first listed.
NCT00084279 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084279 about?
NCT00084279 is a clinical study titled "CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)". To evaluate the safety and tolerability of two different doses of Consensus Interferon-Alpha and Interferon Gamma-1b with or without ribavirin in patients with chronic hepatitis C who are non-responders to PEG-IFN-a 2a or PEG-IFN-a 2b plus ribavirin.
What is the current status of trial NCT00084279?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2004-04. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00084279?
The interventions under investigation include: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin (DRUG).
Who is sponsoring clinical trial NCT00084279?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.